| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Stachyose targets the gut microbiota and acts as a prebiotic. It is an oligosaccharide that can be used as a hypoglycemic agent. Its "target" is the intestinal microbial ecosystem and metabolic pathways. It may also have synergistic effects when combined with other compounds, such as berberine, for improved glycemic control. |
|---|---|
| ln Vitro |
In vitro, Stachyose is used to study its prebiotic effects on gut microbiota. It promotes the growth of beneficial bacteria and is used to investigate the effects of oligosaccharides on microbial composition and activity. Its activity is measured by assessing bacterial growth and metabolic products in culture systems.
|
| ln Vivo |
Berberine (100 mg/kg) plus stachyose (oral gavage; 200 mg/kg; 17 days) together causes superior hypoglycemic effects than berberine alone. The glucose level of diabetic db/db mice is not reduced by stachyose alone. Furthermore, there is no change in the BBR group and a 2.4% and 2.1% drop in mucin ‑2 expression in the Sta + BBR and Sta groups, respectively[1].
In vivo, Stachyose is an oligosaccharide that can be used as a hypoglycemic agent. Studies have shown that berberine (100 mg/kg) plus stachyose (oral gavage; 200 mg/kg; 17 days) together causes superior hypoglycemic effects than berberine alone in diabetic db/db mice. Stachyose alone does not reduce glucose levels, but it enhances the effects of berberine. |
| Enzyme Assay |
In vitro enzyme assays with Stachyose typically involve studying glycoside hydrolases such as α-galactosidase. The compound is used as a substrate to measure enzyme activity. Standard assays involve incubating stachyose with enzyme preparations and measuring the release of monosaccharides by spectrophotometric or chromatographic methods.
|
| Cell Assay |
In vitro cell culture experiments with Stachyose are not typically performed as the compound acts on gut microbiota rather than directly on mammalian cells. However, it may be used in co-culture systems with gut epithelial cells and bacteria to study host-microbe interactions and the effects of prebiotics on barrier function and inflammation.
|
| Animal Protocol |
In vivo animal experiments with Stachyose typically involve administering the compound via oral gavage or dietary incorporation to rodent models of diabetes or metabolic syndrome. Key endpoints include assessment of blood glucose levels, glycemic control, gut microbiota composition (16S sequencing), and metabolic parameters. Studies have evaluated its synergistic effects with berberine in diabetic mice.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Stachyose reflect its role as a prebiotic. As a large oligosaccharide (molecular weight 666.58), it is not absorbed in the small intestine and reaches the colon where it is fermented by gut microbiota. Its effects are mediated through microbial metabolites rather than systemic absorption. It has a melting point of 101-105°C.
|
| Toxicity/Toxicokinetics |
Stachyose has a low toxicity profile as a naturally occurring oligosaccharide. It is generally recognized as safe for consumption. For research use, standard laboratory safety practices are sufficient. It is soluble in water at 50 mg/mL, forming a clear, colorless solution. It should be stored in a sealed, protected environment away from moisture.
|
| References | |
| Additional Infomation |
Stachyose is a tetrasaccharide composed of an α-D-galactosyl-(1→6)-α-D-galactosyl moiety attached to the 6-position of glucose in a sucrose molecule. It is a plant and rodent metabolite. Stachyose belongs to the raffinose family of oligosaccharides and is a tetrasaccharide. Its function is related to that of sucrose and raffinose. Stachyose has been reported in Rehmannia glutinosa, Daphnia magna, and other organisms with relevant data. See also: Oligosaccharides (subclasses).
Stachyose is a tetrasaccharide and raffinose family oligosaccharide that acts as a prebiotic and hypoglycemic agent. It enhances the effects of berberine on glycemic control in diabetic mice. The compound is a plant and rodent metabolite. It is not a drug and has no therapeutic indications. It is available for laboratory research use only. |
| Molecular Formula |
C24H42O21
|
|---|---|
| Molecular Weight |
666.58
|
| Exact Mass |
666.222
|
| CAS # |
470-55-3
|
| Related CAS # |
Stachyose tetrahydrate;10094-58-3;Stachyose hydrate;54261-98-2
|
| PubChem CID |
439531
|
| Appearance |
White to off-white solid powder
|
| Density |
1.84g/cm3
|
| Boiling Point |
1044.2ºC at 760mmHg
|
| Melting Point |
170ºC
|
| Flash Point |
585.3ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.689
|
| LogP |
-8
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
45
|
| Complexity |
933
|
| Defined Atom Stereocenter Count |
19
|
| SMILES |
C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@H]([C@@H]([C@H]([C@H](O3)O[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO)O)O)O)O)O)O)O)O)O)O
|
| InChi Key |
UQZIYBXSHAGNOE-XNSRJBNMSA-N
|
| InChi Code |
InChI=1S/C24H42O21/c25-1-6-10(28)14(32)17(35)21(41-6)39-3-8-11(29)15(33)18(36)22(42-8)40-4-9-12(30)16(34)19(37)23(43-9)45-24(5-27)20(38)13(31)7(2-26)44-24/h6-23,25-38H,1-5H2/t6-,7-,8-,9-,10+,11+,12-,13-,14+,15+,16+,17-,18-,19-,20+,21+,22+,23-,24+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R,6R)-2-[[(2R,3R,4S,5R,6S)-6-[[(2R,3S,4S,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (375.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5002 mL | 7.5010 mL | 15.0020 mL | |
| 5 mM | 0.3000 mL | 1.5002 mL | 3.0004 mL | |
| 10 mM | 0.1500 mL | 0.7501 mL | 1.5002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT05392348
Conditions:Gut Microbiota|microRNAProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
